IHL 0.00% 4.1¢ incannex healthcare limited

Ann: Lease Secured for Psychedelic Clinic, page-66

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 3,848 Posts.
    lightbulb Created with Sketch. 1920
    Hi Alee26
    Remember that myself and @Fractional are using "back of envelope" figures and in no way should form a basis to any portfolio decisions. DYOR is paramount. Also I did explain previously that up front capital costs need to be taken into consideration. Training and all IT devices, Fitout, stock etc. Generally fitout is a major injection but bear in mind we need to fitout clinics.
    Each room will have a therapist desk 2 chairs cabinets/ shelving and possibly a bed. Ingress will consist of reception and chairs. Equipment or computer/IT devises can be leases. The major expense is wheelchair access, wheelchair amenities and a CPR emergency room. Again as most commercial premises comes with amenities this shouldn't be a huge outlay. Training can be provided during each consultation, similar to a hospitals and module lecturing in one of the rooms, not a huge cost. No need for institutional training as all personnel are already qualified in their field

    Risk with the business model is regletory code rates and whether code rebait's given green light to any regulated approved providers. This will effect patient uptake. I have no doubt that a new natural drug with low side effects and have a impact on bettering people's live will be granted regletory code approvals.

    Another huge shot in the arm for this particular business model is supply and demand. Big demand in mental health/inflammatory disease/sleep disorder all needing at a clinical level. Another risk is market capitalisation. These types of IND therapy's have a massive capitalisation world wide. IHL have already scoped AU, US, EU and SAM. Even if there are other players, the market for Psychedelic and cannabis derived medication will no doubt absorb many more providers to come.

    Finally IHL have quite an extensive portfolio. Market capitalisation across all their project is mind boggling.
    Shame market is fixated on macros as healthcare does not collerate. With COH to fund 2 trials and a extensive commercial venture opening Xmas for SHers is looking good.

    Sorry for the long winded post and all IMHO.
    Good Luck @Alee26

 
watchlist Created with Sketch. Add IHL (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.